Chemo Combo Ups Survival in Metastatic Breast Cancer

Share this article:
Chemo Combo Ups Survival in Metastatic Breast Cancer
Chemo Combo Ups Survival in Metastatic Breast Cancer

(HealthDay News) -- The combination of anastrozole and fulvestrant improves survival in patients with hormone receptor-positive metastatic breast cancer, according to a study published in the Aug. 2 issue of the New England Journal of Medicine.

Rita S. Mehta, M.D., from the University of California Irvine Medical Center in Orange, and colleagues randomly assigned postmenopausal women with previously untreated hormone receptor-positive metastatic breast cancer to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or to a combination of anastrozole and fulvestrant (group 2) in a 1:1 ratio.

The researchers found that the median progression-free survival was 13.5 months in group 1 and 15.0 months in group 2 (hazard ratio [HR] for progression or death with combination therapy, 0.80; P = 0.007 by the log-rank test). In all subgroups the combination therapy was more effective than anastrozole alone, with no significant interactions. Despite the fact that 41 percent of the patients in group 1 crossed over to fulvestrant after progression, overall survival was longer with combination therapy (median, 41.3 months in group 1 versus 47.7 months in group 2; HR for death, 0.81; P = 0.05 by the log-rank test). In group 2 there were three deaths possibly associated with treatment. There was no significant difference in the rates of grade 3 to 5 toxic effects between the groups.

"The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard," the authors write.

The study was partially funded by AstraZeneca, which manufactures anastrozole and fulvestrant; several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca.

Full Text (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ACCR: Oral olaparib with chemotherapy beneficial for ovarian cancer

ACCR: Oral olaparib with chemotherapy beneficial for ovarian ...

Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.

Meta-Analysis: Prediabetes tied to increased risk of cancer

Meta-Analysis: Prediabetes tied to increased risk of cancer

Prediabetes has been linked to an increased risk of cancer overall and with increased risks of site-specific cancers, including liver, endometrial, and stomach/colorectal cancer.

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Recommendations are for men whose tumors have grown resistant to hormonal therapies were issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada.